Survival benefit of radical prostatectomy in patients with localized prostate cancer: Estimations of the number needed to treat according to tumor and patient characteristics

Firas Abdollah, Maxine Sun, Jan Schmitges, Rodolphe Thuret, Marco Bianchi, Shahrokh F. Shariat, Alberto Briganti, Claudio Jeldres, Paul Perrotte, Francesco Montorsi, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

Abstract

Purpose: The benefit of active treatment for prostate cancer is a subject of continuous debate. We assessed the relationship between treatment type (radical prostatectomy vs observation) and cancer specific mortality in a large, population based cohort. Materials and Methods: We examined the records of 44,694 patients treated with radical prostatectomy or observation between 1992 and 2005 in the SEER (Surveillance, Epidemiology and End Results)-Medicare linked database. Patients were matched by propensity score. Competing risks analysis was done to test the effect of treatment type on cancer specific mortality after accounting for other cause mortality. The number needed to treat was calculated. All analysis was stratified by prostate cancer risk group, baseline Charlson comorbidity index and patient age. Results: For patients treated with radical prostatectomy vs observation the 10-year cancer specific mortality rate was 5.2% vs 12.8% for high risk prostate cancer, 1.4% vs 3.8% for low-intermediate risk prostate cancer, 2.4% vs 5.8% for a Charlson comorbidity index of 0, 2.3% vs 6.4% for a comorbidity index of 1, 2.5% vs 5.4% for a comorbidity index of 2 or greater, 2.0% vs 4.6% at ages 65 to 69, 2.6% vs 5.6% at ages 70 to 74 and 2.7% vs 8.1% at ages 75 to 80 years (each p

Original languageEnglish
Pages (from-to)73-83
Number of pages11
JournalJournal of Urology
Volume188
Issue number1
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Numbers Needed To Treat
Prostatectomy
Comorbidity
Prostatic Neoplasms
Survival
Mortality
Observation
Neoplasms
Propensity Score
Medicare
Epidemiology
Therapeutics
Databases
Population

Keywords

  • comorbidity
  • prostate
  • prostatectomy
  • prostatic neoplasms
  • SEER program

ASJC Scopus subject areas

  • Urology

Cite this

Survival benefit of radical prostatectomy in patients with localized prostate cancer : Estimations of the number needed to treat according to tumor and patient characteristics. / Abdollah, Firas; Sun, Maxine; Schmitges, Jan; Thuret, Rodolphe; Bianchi, Marco; Shariat, Shahrokh F.; Briganti, Alberto; Jeldres, Claudio; Perrotte, Paul; Montorsi, Francesco; Karakiewicz, Pierre I.

In: Journal of Urology, Vol. 188, No. 1, 07.2012, p. 73-83.

Research output: Contribution to journalArticle

Abdollah, Firas ; Sun, Maxine ; Schmitges, Jan ; Thuret, Rodolphe ; Bianchi, Marco ; Shariat, Shahrokh F. ; Briganti, Alberto ; Jeldres, Claudio ; Perrotte, Paul ; Montorsi, Francesco ; Karakiewicz, Pierre I. / Survival benefit of radical prostatectomy in patients with localized prostate cancer : Estimations of the number needed to treat according to tumor and patient characteristics. In: Journal of Urology. 2012 ; Vol. 188, No. 1. pp. 73-83.
@article{7e0cd489d4764fe9ac7112a1f6556a42,
title = "Survival benefit of radical prostatectomy in patients with localized prostate cancer: Estimations of the number needed to treat according to tumor and patient characteristics",
abstract = "Purpose: The benefit of active treatment for prostate cancer is a subject of continuous debate. We assessed the relationship between treatment type (radical prostatectomy vs observation) and cancer specific mortality in a large, population based cohort. Materials and Methods: We examined the records of 44,694 patients treated with radical prostatectomy or observation between 1992 and 2005 in the SEER (Surveillance, Epidemiology and End Results)-Medicare linked database. Patients were matched by propensity score. Competing risks analysis was done to test the effect of treatment type on cancer specific mortality after accounting for other cause mortality. The number needed to treat was calculated. All analysis was stratified by prostate cancer risk group, baseline Charlson comorbidity index and patient age. Results: For patients treated with radical prostatectomy vs observation the 10-year cancer specific mortality rate was 5.2{\%} vs 12.8{\%} for high risk prostate cancer, 1.4{\%} vs 3.8{\%} for low-intermediate risk prostate cancer, 2.4{\%} vs 5.8{\%} for a Charlson comorbidity index of 0, 2.3{\%} vs 6.4{\%} for a comorbidity index of 1, 2.5{\%} vs 5.4{\%} for a comorbidity index of 2 or greater, 2.0{\%} vs 4.6{\%} at ages 65 to 69, 2.6{\%} vs 5.6{\%} at ages 70 to 74 and 2.7{\%} vs 8.1{\%} at ages 75 to 80 years (each p",
keywords = "comorbidity, prostate, prostatectomy, prostatic neoplasms, SEER program",
author = "Firas Abdollah and Maxine Sun and Jan Schmitges and Rodolphe Thuret and Marco Bianchi and Shariat, {Shahrokh F.} and Alberto Briganti and Claudio Jeldres and Paul Perrotte and Francesco Montorsi and Karakiewicz, {Pierre I.}",
year = "2012",
month = "7",
doi = "10.1016/j.juro.2012.03.005",
language = "English",
volume = "188",
pages = "73--83",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Survival benefit of radical prostatectomy in patients with localized prostate cancer

T2 - Estimations of the number needed to treat according to tumor and patient characteristics

AU - Abdollah, Firas

AU - Sun, Maxine

AU - Schmitges, Jan

AU - Thuret, Rodolphe

AU - Bianchi, Marco

AU - Shariat, Shahrokh F.

AU - Briganti, Alberto

AU - Jeldres, Claudio

AU - Perrotte, Paul

AU - Montorsi, Francesco

AU - Karakiewicz, Pierre I.

PY - 2012/7

Y1 - 2012/7

N2 - Purpose: The benefit of active treatment for prostate cancer is a subject of continuous debate. We assessed the relationship between treatment type (radical prostatectomy vs observation) and cancer specific mortality in a large, population based cohort. Materials and Methods: We examined the records of 44,694 patients treated with radical prostatectomy or observation between 1992 and 2005 in the SEER (Surveillance, Epidemiology and End Results)-Medicare linked database. Patients were matched by propensity score. Competing risks analysis was done to test the effect of treatment type on cancer specific mortality after accounting for other cause mortality. The number needed to treat was calculated. All analysis was stratified by prostate cancer risk group, baseline Charlson comorbidity index and patient age. Results: For patients treated with radical prostatectomy vs observation the 10-year cancer specific mortality rate was 5.2% vs 12.8% for high risk prostate cancer, 1.4% vs 3.8% for low-intermediate risk prostate cancer, 2.4% vs 5.8% for a Charlson comorbidity index of 0, 2.3% vs 6.4% for a comorbidity index of 1, 2.5% vs 5.4% for a comorbidity index of 2 or greater, 2.0% vs 4.6% at ages 65 to 69, 2.6% vs 5.6% at ages 70 to 74 and 2.7% vs 8.1% at ages 75 to 80 years (each p

AB - Purpose: The benefit of active treatment for prostate cancer is a subject of continuous debate. We assessed the relationship between treatment type (radical prostatectomy vs observation) and cancer specific mortality in a large, population based cohort. Materials and Methods: We examined the records of 44,694 patients treated with radical prostatectomy or observation between 1992 and 2005 in the SEER (Surveillance, Epidemiology and End Results)-Medicare linked database. Patients were matched by propensity score. Competing risks analysis was done to test the effect of treatment type on cancer specific mortality after accounting for other cause mortality. The number needed to treat was calculated. All analysis was stratified by prostate cancer risk group, baseline Charlson comorbidity index and patient age. Results: For patients treated with radical prostatectomy vs observation the 10-year cancer specific mortality rate was 5.2% vs 12.8% for high risk prostate cancer, 1.4% vs 3.8% for low-intermediate risk prostate cancer, 2.4% vs 5.8% for a Charlson comorbidity index of 0, 2.3% vs 6.4% for a comorbidity index of 1, 2.5% vs 5.4% for a comorbidity index of 2 or greater, 2.0% vs 4.6% at ages 65 to 69, 2.6% vs 5.6% at ages 70 to 74 and 2.7% vs 8.1% at ages 75 to 80 years (each p

KW - comorbidity

KW - prostate

KW - prostatectomy

KW - prostatic neoplasms

KW - SEER program

UR - http://www.scopus.com/inward/record.url?scp=84862144423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862144423&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.03.005

DO - 10.1016/j.juro.2012.03.005

M3 - Article

C2 - 22578732

AN - SCOPUS:84862144423

VL - 188

SP - 73

EP - 83

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -